Focus on Patients

41. Here's A Template — And Tips — For Assessing And Improving Patient Centricity 11/25/2024

    The Crohn’s & Colitis Foundation shares its guide to reviewing current patient engagement activities and plans for a more patient-centric future.

42. Patient Weighs Altruism, Self-Preservation, And Historical Mistrust In Decision To Enroll In Trial 11/22/2024

    In part three of this series on underserved patient enrollment, patient advocate Bill Allen shares why he enrolled in a clinical trial for both himself and the Black community.

43. Enrollment Mishap Emboldens Patient To Advocate For Minority Participation 11/21/2024

    In part two of this series on underserved patient enrollment, PAN Foundation patient advocate Tony Newberne shares how narrowly missed trial enrollment and how the experience inspired him to advocate for clinical research in minority communities.

44. The PAN Foundation Expands Resources For Underserved Patient Populations 11/20/2024

    In part one of this series on underserved patient enrollment, PAN Foundation CMO Amy Niles discusses the Foundation's efforts to improve access to and affordable healthcare for (including in clinical research) underserved patient populations.

45. UCB Emphasizes Importance Of Patient-Centric Protocols 11/19/2024

    UCB Global Medical Head of Immunology John Ioannou emphasizes the need to partner with the healthcare community, supporting medical and patient organizations, but most importantly, patients to advance the design and execution of patient-centric clinical trials.

46. Call To Include More Pregnant And Breastfeeding Women In Research 11/12/2024

    In this Q&A, UCB Global Head, Women of Childbearing Age Program Marie Teil reiterates the importance of including women of childbearing age, including pregnant and breastfeding women, in clinical research and explains why it’s a priority for UCB.

47. Alexion Rethinks Diversity Metrics And Why Race Alone Isn't Enough 11/8/2024

    Clinical research does not adequately measure diversity, argues Alexion's Adrian Kielhorn. An expert in health economics and outcomes research (HEOR), Kielhorn suggests a more nuanced way of looking at diversity.

48. What Can We Learn From A Highly Diverse Observational Study Of 17,000+ Patients? 11/4/2024

    CMO William Audeh, MD, details Agendia’s diverse, high-enrolling trial and how sponsor companies of investigational trials might benefit from its experiences. 

49. BeiGene Moves Fast, Stays In-House To Conduct Its Cancer Clinical Trials 11/1/2024

    Mark Lanasa, MD, Ph.D. explains how BeiGene gets medicines to more patients, in part by an ability to realize strategic cost and time advantages of a unique (and fast) R&D approach and by bringing clinical operations in-house. 

50. Overcoming Trial Barriers By Looking Through The Lens Of Product Adoption 10/17/2024

    In the final article of this series, Liam and Kim Eves explore how various drug candidates come inherent with barriers to adoption that directly impact how participants and providers engage with clinical research.